ClinicalTrials.gg
Not yet recruitingNCT07566897Updated May 5, 2026

A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors

A Phase 1 interventional study of L19IL2 and Ruxolitinib in Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic and Pancreatic Adenocarcinoma, sponsored by Philogen S.p.A.. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Philogen S.p.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 427 studies in Colorectal Neoplasms with a site in Italy — 102 open to participants now, 142 under way, 18 of them phase 3. Colorectal Neoplasms · Italy.

Planned enrollment
235th of 329
96 · median 215
Started
2026
with 10 others
Phase 1
41 of 427
10 open now
Primary completion
2029-12
later than 128 of 141 live
Registered
419th of 427
by date

Among the 427 studies in Colorectal Neoplasms with a site in Italy, this one is the 235th largest by planned enrollment of the 329 interventional ones that give a count, is one of 11 that started in 2026, is one of 41 in phase 1, reaches primary completion later than 128 of the 141 other live ones, and was the 419th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

102 of the 427 studies in Colorectal Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 427 studies in Colorectal Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.

03

Conditions studied

  • Renal Carcinoma Metastatic
  • Pancreatic Adenocarcinoma Metastatic
  • Pancreatic Adenocarcinoma
  • Metastatic Colorectal Carcinoma (mCRC)

Keywords

  • Ruxolitinib
  • Advanced solid tumors
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed diagnosis of one of the following tumor types for which no further approved systemic treatment options are available:

    1. Unresectable locally advanced or pancreatic ductal adenocarcinoma, that has progressed following:

      • at least one prior line containing FOLFIRINOX and/or gemcitabine plus nab-paclitaxel, and
      • at least one approved regimen (e.g., 5-FU/leucovorin plus liposomal irinotecan), or where these regimens are not suitable due to or prior intolerance
    2. Metastatic proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF V600E-negative colorectal adenocarcinoma, that has progressed following:

      • at least one prior line of systemic therapy including a fluoropyrimidine and oxaliplatin or irinotecan, with or without anti-VEGF and, if RAS wild-type, with or without anti-EGFR, and
      • at least one approved subsequent line of therapy with trifluridine-tipiracil, regorafenib or fruquintinib, or where these agents are not suitable due to contraindication or prior intolerance;
    3. Metastatic clear cell renal cell carcinoma, that has progressed following:

      • at least one prior PD-(L)1-based systemic regimen, and
      • at least one VEGF-targeted tyrosine kinase inhibitor (TKI), or where these treatments are not suitable due to contraindication or prior intolerance
  2. Patients must have no further approved and available therapy options or be documented as ineligible or intolerant.
  3. Patients must have radiographic disease progression on/after the last line of prior treatment.
  4. At least one unidimensionally as defined by v.1.1.
  5. (ECOG) performance status ≤ 2.
  6. Patient has an estimated of at least 12 weeks.
  7. > 10.0 g/dL.
  8. ≥ 100 x 109/L.
  9. (ANC) ≥ 1.5 x 109/L.
  10. Negative TB test (e.g., Mantoux or Quantiferon assay).
  11. Documented negative test for , , excluding active infection is needed. For HBV serology: the determination of HBsAg and anti-HBcAg-Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV: HCV-RNA or HCV antibody test. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  12. Serum creatinine \< 1.5 x and estimated (eGFR) value above 75 mL/min/1.73m2. An age-calibrated definition of Chronic Kidney Disease (CKD) has been proposed to distinguish age-related from disease-related changes in eGFR. For patients younger than 40 years, CKD is defined by estimated Glomerular Filtration Rate (eGFR) below 75 mL/min/1.73m2.
  13. All acute toxic effects (excluding alopecia) of any prior therapy must have been resolved to National Cancer Institute (NCI) (CTCAE v.5.0) Grade ≤ 1.
  14. Women Of (WOCBP) must have negative pregnancy test results at screening. WOCBP must be using, from screening to six months following the last study treatment administration, highly effective methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomized partner. Double-barrier contraception is required.
  15. Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e. spermicidal gel plus condom) from the screening to six months following the last study treatment administration. Double-barrier contraception is required.
  16. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Patients with primary brain tumors, or CNS disease will be excluded.
  2. Chemotherapy, immunotherapy, or radiation therapy at the tumor sites within 4 weeks prior to study treatment start.
  3. Active or history of disease that might deteriorate when receiving an immunostimulatory agent.
  4. Previous or concurrent cancer type that is distinct from the cancer being evaluated in this study. Exception made for any other cancer curatively treated ≥ 2 years prior to study treatment start.
  5. Presence of active severe bacterial or viral infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
  6. Impaired cardiocirculatory functions due to any of the following conditions:

    a History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.

    b Inadequately controlled cardiac arrhythmias including atrial fibrillation. c Heart insufficiency (> Grade II, (NYHA) criteria). d Any abnormalities observed during baseline and Echocardiogram investigations are considered by the investigator.

    e Uncontrolled hypertension defined by systolic blood pressure ≥ 140 mmHg and diastolic blood pressure ≥ 90 mmHg.

    f Ischemic peripheral vascular disease (Grade IIb-IV).

  7. Known arterial aneurysms.
  8. > 3.
  9. Inadequate liver function (, AST, ALP ≥ 2.5 x or total ≥ 2.0 x ULN). At the discretion of the investigator, an increased exclusion threshold for patients with liver can be accepted as follows: ALT, AST and ALP ≥ 5 x ULN.
  10. Known uncontrolled coagulopathy or bleeding disorder, if the subject is being treated for coagulopathy or bleeding disorder and has tests within screening limits, he/she may be included.
  11. Known hepatic cirrhosis or severe pre-existing hepatic impairment ( class B or C).
  12. Moderate to severe respiratory failure.
  13. Patient requires or is taking systemic (> 10 mg/day prednisone or equivalent) or other drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute reactions and asthma/ is not considered an exclusion criterion.
  14. Known history of allergy to an in study medication (e.g. IL2, ruxolitinib) or other human proteins/peptides/antibodies.
  15. Pregnancy or breast-feeding.
  16. Severe diabetic retinopathy.
  17. Recovery from major trauma including surgery within 4 weeks prior to enrollment.
  18. Patient with iatrogenic or pathologic severe immune suppression.
  19. Requirement of concurrent use of other anti-cancer treatments or agents other than study medication.
  20. Patient taking herbal medications within 7 days prior to study treatment start.
  21. Anticoagulation therapy with P2Y12 antagonists (e.g., clopidogrel, ticagrelor) and vitamin K antagonists (e.g., phenprocoumon, warfarin).
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Experimental L19IL2 dose escalation intravenous administration

    Drug: L19IL2

  • Experimental
    Experimental L19IL2 + Ruxolitinib dose escalation intravenous administration

    Drug: L19IL2 · Drug: Ruxolitinib

  • Experimental
    Experimental L19IL2 + Ruxolitinib dose expansion intravenous administration

    Drug: L19IL2 · Drug: Ruxolitinib

Interventions

06

What researchers measure

Primary outcomes

  1. STEP A and STEP B: DLT

    Occurrence of Dose Limiting Toxicity (DLT) of L19IL2 alone and in combination with ruxolitinib

    Time frame: From Day 1 to Day 28 of the treatment

  2. Safety (AE)

    Adverse Events (AEs) of administration of L19IL2 alone and in combination with ruxolitinib, assessed by Common Toxicity Criteria (version 5.0, CTCAE)

    Time frame: Through study completion, an average of 1 year

  3. Safety (SAEs)

    Serious Adverse Events(SAEs) of administration of L19IL2 alone and in combination with ruxolitinib, assessed by Common Toxicity Criteria (version 5.0, CTCAE)

    Time frame: Through study completion, an average of 1 year

  4. Safety (DILI)

    Evaluation of possible Drug Induce Liver Injury (DILI), caused by L19IL2 alone and in combination with ruxolitinib, assessed by Common Toxicity Criteria (version 5.0, CTCAE)

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Overall Response Rate (ORR)

    Overall Response Rate (ORR, including CR and PR) as per RECIST 1.1

    Time frame: Every 8 weeks from treatment start (every 2 cycles; each cycle is 28 days)

  2. Disease Control Rate (DCR)

    Disease Control Rate (DCR, including CR, PR, and SD) as per RECIST 1.1

    Time frame: Every 8 weeks from treatment start (every 2 cycles; each cycle is 28 days)

  3. DoR

    Duration of Response (DoR)

    Time frame: Every 8 weeks from treatment start (every 2 cycles; each cycle is 28 days)

  4. PSF

    Progression Free Survival (PFS)

    Time frame: Every 8 weeks from treatment start (every 2 cycles; each cycle is 28 days)

  5. Human anti-fusion protein antibody (HAFA)

    Blood samples will be obtained to assess the potential development of antibody to L19IL2.

    Time frame: Day 1 and 8 of cycle 1; Day 1 of cycle 2, 3, 4, 5, 6. Each cycle is 28 days.

  6. Maximum Plasma Concentration (Cmax)

    Maximum observed plasma concentration (Cmax) of L19IL2 and ruxolitinib following administration

    Time frame: Day 1, 2, 8, 15, 22, 23 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 5, and 6 (each cycle is 28 days)

  7. Time to Maximum Plasma Concentration (Tmax)

    Time to reach maximum observed plasma concentration (Tmax) of L19IL2 and ruxolitinib.

    Time frame: Day 1, 2, 8, 15, 22, 23 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 5, and 6 (each cycle is 28 days)

  8. Area Under Concentration (AUC)

    Area under the plasma concentration-time curve (AUC) of L19IL2 and ruxolitinib

    Time frame: Day 1, 2, 8, 15, 22, 23 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 5, and 6 (each cycle is 28 days)

  9. Terminal Elimination Half-life (t½)

    Terminal elimination half-life (t½) of L19IL2 and ruxolitinib

    Time frame: Day 1, 2, 8, 15, 22, 23 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 5, and 6 (each cycle is 28 days)

07

Study locations

1 site
  • Fondazione Policlinico Gemelli Unità di Fase 1: Unità di Farmacologia Clinica
    Roma, Roma 00168, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Dec 2029, 43 months later.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 43 months is close to that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
May 5, 2026
StartEst.
May 1, 2026
Primary completionEst.
Dec 2029
CompletionEst.
May 2030
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07566897
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
May 5, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
May 2030 (estimated)
Last update
May 5, 2026

Study contacts

Claudio Nanni
Contact
regulatory@philogen.com
+39 057717816
Federica Bastioli
Contact
regulatory@philogen.com
+39 057717816

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darleukin

Start the discussion